The Antitumor Potential of λ-Carrageenan Oligosaccharides on Gastric Carcinoma by Immunomodulation
2023
Min Tang | Leilei Zhai | Juanjuan Chen | Feng Wang | Haimin Chen | Wei Wu
Gastric carcinoma is a frequently detected malignancy worldwide, while its mainstream drugs usually result in some adverse reactions, including immunosuppression. &lambda:-carrageenan oligosaccharides (COS) have attracted increasing attention as potential anticancer agents due to their ability to enhance immune function. Our current work assessed the antitumor mechanism of &lambda:-COS using BGC-823 cells. Our findings indicated that &lambda:-COS alone did not have a significant impact on BGC-823 cells in vitro: however, it was effective in inhibiting tumor growth in vivo. When THP-1 cells were pre-incubated with &lambda:-COS and used to condition the medium, BGC-823 cells in vitro displayed a concentration-dependent induction of cell apoptosis, nuclear damage, and the collapse of mitochondrial transmembrane potential. These findings suggested that the antineoplastic effect of &lambda:-COS was primarily due to its immunoenhancement property. Treatment with &lambda:-COS was found to significantly enhance the phagocytic capability of macrophages, increase the secretion of TNF-&alpha: and IFN-&gamma:, and improve the indexes of spleen and thymus in BALB/c mice. In addition, &lambda:-COS was found to inhibit the growth of BGC-823-derived tumors in vitro by activating the Par-4 signaling pathway, which may be stimulated by the combination of TNF-&alpha: and IFN-&gamma:. When used in combination with 5-FU, &lambda:-COS demonstrated enhanced anti-gastric carcinoma activity and improved the immunosuppression induced by 5-FU alone. These findings suggested that &lambda:-COS could be used as an immune-modulating agent for chemotherapy.
Afficher plus [+] Moins [-]Informations bibliographiques
Cette notice bibliographique a été fournie par Multidisciplinary Digital Publishing Institute
Découvrez la collection de ce fournisseur de données dans AGRIS